A comparison of arthroscopic synovial biopsy based targeted biologic therapy versus conventional therapy in rheumatoid arthritis (RA)

Not Applicable

Recruiting

• Conditions: Rheumatoid Arthritis; Inflammatory and Immune System - Rheumatoid arthritis

• Registration Number: ACTRN12611001202954
• Lead Sponsor: Professor Malcolm D Smith

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-11-23
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

Anti cyclic citrullinated peptide (CCP) positive active (>/=2 joints) rheumatoid arthritis, duration of disease </=12 months

Exclusion Criteria

Previously received DMARD/ bDMARD for RA; ANA positive >320, hepatitis B/ C/ HIV positivity, concomitant treatment with experimental drug

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to achieve remission between the two study arms using composite measures of disease activity: DAS28 (disease activity score using 28 joint count) and ACR (American College of Rheumatology) and EULAR (European League against Rheumatism) response criteria[6 months, 12 months]